Nonarteritic anterior ischemic optic neuropathy.

Area of Science:

• Ophthalmology
• Neurology

Background:

• Nonarteritic anterior ischemic optic neuropathy (NAION) lacks a universally accepted, proven treatment.
• Current therapeutic approaches are largely empirical, including antithrombotics, vasodynamic agents, optic disc edema reduction, and neuroprotection.
• Many proposed treatments for NAION have been inadequately studied or prematurely evaluated.

Purpose of the Study:

• To review current treatment strategies for NAION.
• To provide recommendations for managing NAION based on available evidence and clinical experience.
• To highlight the need for further rigorous clinical trials.

Main Methods:

• Literature review of existing studies on NAION treatments.
• Analysis of the evidence for various therapeutic interventions.
• Clinical opinion based on the understanding of NAION pathophysiology and risk factors.

Main Results:

• Evidence supporting antithrombotic agents in NAION is currently lacking.
• Antiplatelet agents, while not specifically studied in acute NAION, are recommended for secondary prevention due to their established role in stroke prevention.
• Aggressive management of vascular risk factors is advised for patients with NAION.
• Limited and debated evidence exists for oral steroids in reducing disc edema and improving visual outcomes.
• Neuroprotective strategies have not demonstrated efficacy in NAION.

Conclusions:

• Aggressive risk-factor management and antiplatelet therapy are recommended for NAION.
• Aspirin is recommended for secondary prevention of NAION, primarily for its proven benefits in stroke prevention.
• Oral steroids may be considered on a case-by-case basis for acute NAION, but routine recommendation requires further randomized clinical trial data.
• Current neuroprotective strategies are not recommended.
• Referral to low vision services is important for improving functional visual outcomes.